Moderna launches late-stage trial of mRNA bird flu vaccine
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Subscribe To Our Newsletter & Stay Updated